Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Céleste Lebbé"'
Autor:
Jeffrey E. Gershenwald, Michael T. Tetzlaff, Peter A. Prieto, Jennifer L. McQuade, Charlotte E. Ariyan, Jonathan S. Zager, David F. McDermott, Adil Daud, Christian U. Blank, Kim Margolin, Richard A. Scolyer, Brett W. Carter, Elizabeth M. Burton, Richard D. Carvajal, Jeffrey A. Sosman, Alexander N. Shoushtari, April K.S. Salama, Scott E. Woodman, Tina J. Hieken, Vernon K. Sondak, Douglas S. Tyler, Jeffrey E. Lee, Frances C. Wright, Omid Hamid, David E. Fisher, Tanja D. de Gruijl, Miles C. Andrews, Michael C. Lowe, John M. Kirkwood, Keith T. Flaherty, Mark B. Faries, Grant A. McArthur, Dirk Schadendorf, Alexander C.J. van Akkooi, Alberto Fusi, Bart A. van de Wiel, James Larkin, Ken K. Tanabe, Jane L. Messina, Jennifer A. Wargo, Rodabe N. Amaria, Jonathan Cohen, Shaneen Sandhu, Andrew J. Spillane, Reinhard Dummer, Robert Antdbacka, Michael A. Postow, Michael D. Farwell, Céleste Lebbé, Jason J. Luke, Genevieve M. Boland, Tara C. Mitchell, David H. Lawson, Elisa A. Rozeman, Diwakar Davar, Caroline Robert, Kathryn Bollin, Ryan J. Sullivan, Michael A. Davies, Matteo S. Carlino, Isabella C. Glitza, Robyn P. M. Saw, Merrick I. Ross, Axel Hauschild, Teresa M. Petrella, Paolo A. Ascierto, Serigne Lo, Igor Puzanov, Samra Turajlic, Angela Hong, Roland L. Bassett, Keith A. Delman, Georgina V. Long, Hussein Abdul-Hassan Tawbi, Susan M. Swetter, Janis M. Taube, Alexander M.M. Eggermont, John F. Thompson, Donald A. Berry, Leslie A. Fecher, Matthew S. Block, Alexander M. Menzies, David E. Gyorki, Helen Rizos
Publikováno v:
The Lancet Oncology. 20:e378-e389
Advances in the treatment of metastatic melanoma have improved responses and survival. However, many patients continue to experience resistance or toxicity to treatment, highlighting a crucial need to identify biomarkers and understand mechanisms of
Autor:
Piotr Rutkowski, Lars Bastholt, Ralf Gutzmer, Claus Garbe, Virginia Ferraresi, Marta Nyakas, Omid Hamid, Joanna Pikiel, Jean-Jacques Grob, Paolo A. Ascierto, Céleste Lebbé, Caroline Robert, Delphine Hennicken, Vanna Chiarion-Sileni, Michael Smylie, Gabriella Liszkay, Florent Grange, Catriona M. McNeil, Luc Thomas, Dirk Schadendorf, Andrzej Mackiewicz, Michele Del Vecchio, Christoph Hoeller, Carmen Loquai, Michele Maio, Inge Marie Svane, Anila Qureshi, Brigitte Dréno, Ana Arance, Laurent Mortier
Publikováno v:
Ascierto, P A, Del Vecchio, M, Robert, C, Mackiewicz, A, Chiarion-Sileni, V, Arance, A, Lebbe, C, Bastholt, L, Hamid, O, Rutkowski, P, McNeil, C, Garbe, C, Loquai, C, Dreno, B, Thomas, L, Grob, J-J, Liszkay, G, Nyakas, M, Gutzmer, R, Pikiel, J, Grange, F, Hoeller, C, Ferraresi, V, Smylie, M, Schadendorf, D, Mortier, L, Svane, I M, Hennicken, D, Qureshi, A & Maio, M 2017, ' Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma : a randomised, double-blind, multicentre, phase 3 trial ', Lancet Oncology, vol. 18, no. 5, pp. 611-622 . https://doi.org/10.1016/S1470-2045(17)30231-0
Articles Lancet Oncol
Articles Lancet Oncol, 2017, 18 (5), pp.611-622. 〈10.1016/S1470-2045(17)30231-0〉
Lancet Oncology
Lancet Oncology, 2017, 18 (5), pp.611-622. ⟨10.1016/S1470-2045(17)30231-0⟩
Lancet Oncology, Elsevier, 2017, 18 (5), pp.611-622. ⟨10.1016/S1470-2045(17)30231-0⟩
Articles Lancet Oncol
Articles Lancet Oncol, 2017, 18 (5), pp.611-622. 〈10.1016/S1470-2045(17)30231-0〉
Lancet Oncology
Lancet Oncology, 2017, 18 (5), pp.611-622. ⟨10.1016/S1470-2045(17)30231-0⟩
Lancet Oncology, Elsevier, 2017, 18 (5), pp.611-622. ⟨10.1016/S1470-2045(17)30231-0⟩
BACKGROUND: A phase 2 trial suggested increased overall survival and increased incidence of treatment-related grade 3-4 adverse events with ipilimumab 10 mg/kg compared with ipilimumab 3 mg/kg in patients with advanced melanoma. We report a phase 3 t
Autor:
Alexander M.M. Eggermont, Stefan Suciu, Céleste Lebbé, Vanna Chiarion-Sileni, Corneel Coens, Michael Smylie, Alessandro Testori, Omid Hamid, Srividya Kotapati, Andrew Bottomley, Jon M. Richards, Jeffrey S. Weber, Reinhard Dummer, Jean-Jacques Grob, Virginia Ferraresi, Michele Maio, Veerle de Pril, Caroline Robert, Henrik Schmidt, Paolo A. Ascierto, Jedd D. Wolchok
Publikováno v:
Coens, C, Suciu, S, Chiarion-Sileni, V, Grob, J-J, Dummer, R, Wolchok, J D, Schmidt, H, Hamid, O, Robert, C, Ascierto, P A, Richards, J M, Lebbé, C, Ferraresi, V, Smylie, M, Weber, J S, Maio, M, Bottomley, A, Kotapati, S, de Pril, V, Testori, A & Eggermont, A M M 2017, ' Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial ', Lancet Oncology, vol. 18, no. 3, pp. 393-403 . https://doi.org/10.1016/S1470-2045(17)30015-3
BACKGROUND:The EORTC 18071 phase 3 trial compared adjuvant ipilimumab with placebo in patients with stage III melanoma. The primary endpoint, recurrence-free survival, was significantly longer in the ipilimumab group than in the placebo group. Invest
Autor:
Paul Nghiem, Kevin M. Chin, Céleste Lebbé, Howard L. Kaufman, Anja von Heydebreck, Isaac Brownell, Shailender Bhatia, Sandra P. D'Angelo, Michele Milella, Jochen H. Lorch, Omid Hamid, Lisa Mahnke, Gerald P. Linette, Kent C. Shih, Jean Marie Cuillerot, Karl D. Lewis, Jeffery S. Russell, Patrick Terheyden
Publikováno v:
The Lancet Oncology. 17:1374-1385
Summary Background Merkel cell carcinoma is a rare, aggressive skin cancer with poor prognosis in patients with advanced disease. Current standard care uses various cytotoxic chemotherapy regimens, but responses are seldom durable. Tumour oncogenesis